Search Results - "Carmena, Marı́a J."
-
1
Anticancer Activity of Dendriplexes against Advanced Prostate Cancer from Protumoral Peptides and Cationic Carbosilane Dendrimers
Published in Biomacromolecules (11-03-2019)“…The interaction of neuropeptides, vasoactive intestinal peptide (VIP), or growth hormone-releasing hormone (GHRH), with a cationic carbosilane dendrimer forms…”
Get full text
Journal Article -
2
Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells
Published in Molecular and cellular endocrinology (05-05-2017)“…The involvement of growth hormone-releasing hormone (GHRH) in several relevant processes that contribute to prostate cancer progression was analyzed. Firstly,…”
Get full text
Journal Article -
3
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists
Published in Investigational new drugs (01-06-2020)“…Summary Prostate cancer is the second leading cause of cancer-related deaths among men in developed countries. Neuroendocrine prostate cancer, in particular,…”
Get full text
Journal Article -
4
VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells
Published in Cellular signalling (01-02-2015)“…The nuclear factor κB (NF-κB) is a powerful activator of angiogenesis, invasion and metastasis. Transactivation and nuclear localisation of NF-κB is an index…”
Get full text
Journal Article -
5
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer
Published in Peptides (New York, N.Y. : 1980) (01-11-2010)“…▶ Endocytosis and nuclear translocation of peripheral GPCRs. ▶ VPAC 1 receptor is localized in cell nuclear fraction in human breast. ▶ VPAC 1 receptor is…”
Get full text
Journal Article -
6
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells
Published in Molecular and cellular endocrinology (10-04-2009)“…We analyzed the cross-talk between receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors…”
Get full text
Journal Article -
7
Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells
Published in Peptides (New York, N.Y. : 1980) (01-12-2016)“…•GHRH induces transactivation of EGFR by two different molecular mechanisms.•GHRH stimulates a ligand-independent activation of EGFR involving PKA and…”
Get full text
Journal Article -
8
Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma
Published in Molecular and cellular endocrinology (30-01-2013)“…► Vasoactive intestinal peptide (VIP) increases adhesion of renal carcinoma cells. ► VIP decreases migration and extracellular-matrix degradation in tumor…”
Get full text
Journal Article -
9
RNA interference-directed silencing of VPAC₁ receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells
Published in Molecular and cellular endocrinology (02-01-2012)“…We used small-interference RNA (siRNA) to explore the mechanisms of some vasoactive intestinal peptide (VIP) actions on human breast cancer cells. Transfection…”
Get full text
Journal Article -
10
Regulation of the expression of protein kinase C isoenzymes in rat ventral prostate: effects of age, castration and flutamide treatment
Published in Life sciences (1973) (27-09-2002)“…Protein kinase C (PKC) isoenzymes are involved in cell function, growth, apoptosis and neoplastic transformation in the prostate gland. We detected by means of…”
Get full text
Journal Article -
11
Inhibitory effects of antagonists of growth hormone‐releasing hormone on growth and invasiveness of PC3 human prostate cancer
Published in International journal of cancer (15-02-2013)“…New approaches are needed to the therapy of advanced prostate cancer. This study determined the effect of growth hormone‐releasing hormone (GHRH) antagonists,…”
Get full text
Journal Article -
12
Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation
Published in Biochimica et biophysica acta (01-10-2012)“…Clear renal cell carcinoma (cRCC) is an aggressive and fatal neoplasm. The present work was undertaken to investigate the antiproliferative potential of…”
Get full text
Journal Article -
13
Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN‐215) and a bombesin antagonist (RC‐3095)
Published in International journal of cancer (15-10-2010)“…Bombesin (BN) and gastrin‐releasing peptide (GRP) have been shown to stimulate the growth of human prostate cancer in vivo and in vitro by mechanisms initiated…”
Get full text
Journal Article -
14
Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells
Published in Peptides (New York, N.Y. : 1980) (01-12-2012)“…► VIP decreases ROS levels reached by H2O2-induced oxidative stress. ► VIP increases Bcl-2 and decreases Bax in H2O2-injured HK2 human renal cells. ► The…”
Get full text
Journal Article -
15
Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer
Published in Oncotarget (09-08-2016)“…Growth hormone-releasing hormone (GHRH) and its receptors have been implicated in the progression of various tumors. In vitro and in vivo studies have…”
Get full text
Journal Article -
16
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression
Published in The international journal of biochemistry & cell biology (01-08-2014)“…•VIP increases cell adhesion and ROS production in A498 cells.•VIP decreases VEGF165 secretion in A498 renal cancer cells.•VIP induces p53 expression (at mRNA…”
Get full text
Journal Article -
17
Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1
Published in Cancer letters (18-12-2010)“…Abstract The carcinogenic potential of vasoactive intestinal peptide (VIP) was analyzed in non-tumor human prostate epithelial cells (RWPE-1) and in vivo…”
Get full text
Journal Article -
18
Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice
Published in Cancer letters (09-08-2013)“…Highlights • VIP exerted antitumoral effects in renal cell carcinoma xenografts. • VIP upregulated p53 and decreased nuclear β-catenin translocation. • VIP…”
Get full text
Journal Article -
19
Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells
Published in The Prostate (15-05-2009)“…BACKGROUND There is little known on the involvement of vasoactive intestinal peptide (VIP) in the metastatic cascade of human prostate cancer, that is, cell…”
Get full text
Journal Article -
20
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells
Published in Regulatory peptides (04-12-2007)“…Previous studies have shown that vasoactive intestinal peptide (VIP) and its receptors (VPAC 1 and VPAC 2 receptors) are involved in promotion and growth of…”
Get full text
Journal Article